

# Recurrent single-molecule epistates define tumor methylome differences

Huy Q. Dinh

Ben Berman lab @ USC Epigenome Center


University of Southern California

# Tumor whole genome DNA methylation profiling by bisulfite sequencing

- ~ 10K samples profiled by Illumina Infinium 27K & 450K microarray platforms within TCGA projects.
- Whole Genome Bisulfite Sequencing (WGBS)
  - Methylation profile of 28M CpGs with more sequence variation information.
  - WGBS on 47 TCGA patient samples completed
  - >15x sequence coverage / sample
- Identification of recurrent Differentially Methylated Regions (DMRs) across multiple tumors based on single-molecule analysis of WGBS.

Sample s	#	Sample s	#
LUAD	6	GBM	6
LUSC	5	BRCA	6
BLCA	7	STAD	5
UCEC	6	COAD	3
		READ	3


# Tumor heterogeneity in WGBS




**Learning epistate mixture based on Expectation Maximization (EM)**

Extended from allelic methylation model (Fang et al, PNAS 2012)


# Estimating within-sample epistate frequencies



# Using epistates to identify DMRs



# Genome-wide scanning for epistates




# Estimating tumor purity based on epistate frequencies

chr12:133464725 (168 bps) 133464892

Epistate  $\alpha$  (blue dots)  
Epistate  $\beta$  (red dots)

## Leukocytes

PBMC 0 % CD4 0 %




## Colon tumors

COAD 1 76.27 %




## Adjacent normals




BRCA 0 % COAD 0 %




COAD 2 53.85 %



16K loci



# Epistate estimate tumor purity highly correlated with ABSOLUTE estimation





# Epistates can be detected at low frequency

chr1:145039592

(239 bps)


145039830

Epistate  $\alpha$  .....  
Epistate  $\beta$  .....

COAD1: 40.34%

COAD2: 13.82%

COAD3: 15.79%




**Methylated  
epistate found  
in only COAD  
tumors**

Adjacent Normals




Unmethylated Tumors




...

# Epistate DMR example: Epigenetically silenced distal element (SMAD3)




Epistate  $\alpha$  ●●●●●●●●●●  
 Epistate  $\beta$  ●●●●●●●●●●


Leukocytes & Adjacent normals



Unmethylated tumors




Methylated tumors




## SMAD3

mediate multiple signaling pathways including Wnt signaling and cell cycle




Log2 RSEM – gene expression




Epistate frequency



# Summary



0.999	5e-10	} 83%
6e-10	0.999	
6e-10	0.999	
6e-10	0.999	
6e-10	0.999	
4e-10	0.999	



- We developed **single-molecule epistate method** for analyzing multiple WGBS samples/tumors.
- **Epistate applications:**
  - Methylation-based tumor purity estimation.
  - Differentially Methylated Regions finding reveals epigenetically silenced (regulatory) regions at (low) epistate frequencies.

# Acknowledgements

- **Berman Lab**
  - Yaping Liu
  - Lijing Yao
  - **Ben Berman**
- **JHU**
  - Steve Baylin
- **USC Epigenome Center**
  - **Peter Laird**
  - **Hui Shen**
  - Toshi Hinoue
  - Dan Weisenberger
  - Charlie Nicolet
  - Zack Ramjan
  - Kim Siegmund
  - Natalia Shatokhina
  - Selene Tyndale
  - Helen Truong



The Cancer Genome Atlas  *Understanding genomics  
to improve cancer care*

NCI grant #1U24CA143882